Kilitch Drugs (India)
Healthcare
KILITCH NSE
₹208.91 +6.78 (+3.35%)
- P/E
- 24.32
Close 4 Nov 2026 ₹208.91 +20.41 +10.8% 1Y
Start ₹188.50
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 13.40%
- Debt to Equity
- 0.32
- EPS (TTM)
- ₹8.59
- Book Value
- ₹79.99
- Market Cap
- —
- P/E (TTM)
- 24.32
- P/B
- 2.61
- ROE
- 10.60%
- Dividend Yield
- 0.00%
- EBITDA
- ₹47.80 Cr
- 52W High
- ₹267.90
- 52W Low
- ₹117.25
- Day Range
- ₹202.01 – ₹210.60
- Volume
- 36,118
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Kilitch Drugs (this company) | ₹208.91 | 24.32 | ₹719 Cr | 2.61 | 0.00% | 10.60% | 13.40% | ₹237 Cr | ₹29 Cr |
| Median 8 companies | ₹1,587.70 | 37.20 | ₹1,25,337 Cr | 4.57 | 0.44% | 16.25% | 16.65% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
50 Average
Data confidence 100/100
Category scores
- Quality
- 28
- Poor
- Returns, margins, earnings quality 22% weight
- Valuation
- 49
- Average
- Cheap vs sector & own history 24% weight
- Growth
- 50
- Average
- Sales & profit trajectory 9% weight
- Financial Health
- 45
- Average
- Solvency, leverage, coverage 9% weight
- Momentum
- 63
- Good
- Trend strength, vol-adjusted 12% weight
- Ownership
- 63
- Good
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Company has delivered good profit growth of 54.7% CAGR over last 5 years
- Company's median sales growth is 28.4% of last 10 years
Weaknesses
5- Stock is trading at 2.99 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 10.2% over last 3 years.
- Company has high debtors of 186 days.
- Promoter holding has decreased over last 3 years: -5.46%
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bullish | 4 | 7 | 8 |
| Oscillators | Bearish | 2 | 7 | 0 |
| Moving Averages | Strong Bullish | 2 | 0 | 8 |
Oscillators
Bearish
Bearish
2
Neutral
7
Bullish
0
Overall
Bullish
Bearish
4
Neutral
7
Bullish
8
Moving Averages
Strong Bullish
Bearish
2
Neutral
0
Bullish
8
Key readings
- RSI (14)
- 48.12
- Neutral
- MACD (12,26,9)
- −2.34
- Bearish
- SMA (50)
- 204.83
- Bullish
- SMA (200)
- 177.29
- Bullish
As of
Analyst Rating
Based on 1 analysts
1 of 1 analyst rates Buy, 0 Hold, 0 Sell.
As of
BUY
1
100% HOLD
0
0% SELL
0
0% Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | +27.32% |
|---|---|
| 5Y | +28.15% |
| 3Y | +18.84% |
| 1Y | +18.69% |
| TTM | +14.04% |
Net profit
| 10Y | Turned to profit |
|---|---|
| 5Y | +49.63% |
| 3Y | +55.36% |
| 1Y | +20.00% |
| TTM | +9.28% |
Operating cash flow
| 10Y | +3.51% |
|---|---|
| 5Y | −12.20% |
| 3Y | +100.00% |
| 1Y | +33.33% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +34.79 pp |
|---|---|
| 5Y | +8.39 pp |
| 3Y | +2.88 pp |
| 1Y | −0.42 pp |
| TTM | −0.42 pp |
Revenue by year
| Mar 2017 | ₹27.00 Cr |
|---|---|
| Mar 2018 | ₹51.00 Cr |
| Mar 2019 | ₹82.00 Cr |
| Mar 2020 | ₹53.00 Cr |
| Mar 2021 | ₹68.00 Cr |
| Mar 2022 | ₹114 Cr |
| Mar 2023 | ₹140 Cr |
| Mar 2024 | ₹154 Cr |
| Mar 2025 | ₹198 Cr |
| Mar 2026 | ₹235 Cr |
Net profit by year
| Mar 2017 | −₹9.00 Cr |
|---|---|
| Mar 2018 | ₹5.00 Cr |
| Mar 2019 | ₹4.00 Cr |
| Mar 2020 | ₹1.00 Cr |
| Mar 2021 | ₹4.00 Cr |
| Mar 2022 | ₹6.00 Cr |
| Mar 2023 | ₹8.00 Cr |
| Mar 2024 | ₹14.00 Cr |
| Mar 2025 | ₹25.00 Cr |
| Mar 2026 | ₹30.00 Cr |
Analyst Forecasts
Forecast For
Mar 27 consensus · Price
₹169.00 −20.8% vs Sep 26
Reported High Mean Low
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 36.56 | 41.2 | 31.79 | 44.82 | 33.45 | 47.47 | 56.17 | 61.23 | 43.14 | 48.92 | 53.81 | 89.6 | 44.88 |
| Expenses | 30.38 | 32.58 | 29.51 | 37.74 | 31.79 | 41.37 | 47.44 | 46.64 | 39.88 | 43.88 | 47.66 | 67.46 | 41.94 |
| Operating Profit | 6.18 | 8.62 | 2.28 | 7.08 | 1.66 | 6.1 | 8.73 | 14.59 | 3.26 | 5.04 | 6.15 | 22.14 | 2.94 |
| OPM % | 16.9% | 20.92% | 7.17% | 15.8% | 4.96% | 12.85% | 15.54% | 23.83% | 7.56% | 10.3% | 11.43% | 24.71% | 6.55% |
| Other Income | 0.56 | 0.49 | 2.96 | 0.47 | 2.57 | 5.16 | 1.73 | 1.7 | 2.56 | 6.66 | 1.53 | 0.49 | 2.9 |
| Interest | 1.5 | 1.51 | 1.6 | 1.32 | 1.73 | 0.31 | 1.4 | 1.6 | 1.53 | 1.44 | 1.15 | 1.44 | 0.88 |
| Depreciation | 0.79 | 0.82 | 0.81 | 0.93 | 0.85 | 0.61 | 0.81 | 0.85 | 0.84 | 0.86 | 0.94 | 0.98 | 1.09 |
| PBT | 4.45 | 6.78 | 2.82 | 5.3 | 1.65 | 10.35 | 8.25 | 13.84 | 3.45 | 9.4 | 5.59 | 20.21 | 3.86 |
| Tax % | 32.67% | 24.93% | 38.16% | 30.57% | 93.33% | 16.73% | 32% | 26.23% | 34.49% | 14.47% | 22.9% | 26.37% | 48.84% |
| Net Profit | 3.06 | 5.09 | 1.74 | 3.68 | 0.11 | 8.61 | 5.61 | 10.22 | 2.27 | 8.04 | 4.31 | 14.88 | 1.97 |
| EPS (₹) | 0.99 | 1.35 | 0.83 | 1.03 | 0.38 | 2.46 | 1.7 | 2.97 | 0.87 | 2.34 | 1.27 | 4.15 | 0.83 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 19 | 21 | 27 | 51 | 82 | 53 | 68 | 114 | 140 | 154 | 198 | 235 | 237 |
| Expenses | 21 | 25 | 28 | 45 | 75 | 53 | 63 | 104 | 122 | 130 | 167 | 198 | 201 |
| Operating Profit | −2 | −4 | −1 | 6 | 7 | 0 | 5 | 10 | 18 | 24 | 32 | 37 | 36 |
| OPM % | −9% | −19% | −2% | 11% | 9% | 0.8% | 8% | 9% | 13% | 16% | 16% | 16% | 15% |
| Other Income | 3 | 2 | 1 | 3 | 4 | 4 | 3 | 3 | 3 | 4 | 11 | 11 | 12 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 5 | 6 | 5 | 6 | 5 |
| Depreciation | 2 | 10 | 10 | 2 | 2 | 2 | 2 | 2 | 4 | 3 | 3 | 4 | 4 |
| PBT | −1 | −12 | −9 | 6 | 9 | 2 | 5 | 10 | 12 | 19 | 34 | 39 | 39 |
| Tax % | −70% | −4% | −5% | 16% | 55% | 48% | 27% | 35% | 31% | 30% | 28% | 24% | — |
| Net Profit | 0 | −11 | −9 | 5 | 4 | 1 | 4 | 6 | 8 | 14 | 25 | 30 | 29 |
| EPS (₹) | −0.1 | −3.89 | −3.09 | 1.72 | 1.15 | 0.25 | 1.09 | 2.17 | 3.08 | 4.17 | 7.63 | 8.63 | 8.59 |
| Div. Payout % | 0% | 0% | 0% | 13% | 20% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 14 | 15 | 15 | 15 | 16 | 16 | 16 | 16 | 35 |
| Reserves | 107 | 95 | 88 | 98 | 106 | 103 | 112 | 124 | 136 | 160 | 186 | 245 |
| Borrowings | 0 | 0 | 1 | 1 | 9 | 13 | 15 | 20 | 22 | 32 | 49 | 89 |
| Other Liabilities | 7 | 8 | 11 | 15 | 13 | 12 | 61 | 50 | 46 | 32 | 61 | 89 |
| Total Liabilities | 127 | 117 | 113 | 128 | 144 | 143 | 203 | 210 | 220 | 240 | 313 | 458 |
| Fixed Assets | 9 | 42 | 33 | 33 | 32 | 32 | 30 | 65 | 64 | 62 | 64 | 67 |
| CWIP | 0 | 0 | 1 | 3 | 20 | 30 | 65 | 3 | 4 | 6 | 47 | 140 |
| Investments | 72 | 49 | 53 | 56 | 53 | 52 | 60 | 71 | 62 | 72 | 72 | 75 |
| Other Assets | 46 | 25 | 26 | 35 | 38 | 30 | 47 | 71 | 90 | 100 | 129 | 176 |
| Total Assets | 127 | 117 | 113 | 128 | 144 | 143 | 203 | 210 | 220 | 240 | 313 | 458 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | −8 | 17 | 1 | 1 | 0 | 4 | 46 | 6 | 3 | −2 | 18 | 24 |
| Investing | −31 | −20 | −2 | −4 | −14 | −10 | −38 | −15 | 8 | −8 | −40 | −100 |
| Financing | 0 | 0 | 0 | 6 | 17 | 1 | 2 | 7 | −1 | 9 | 13 | 82 |
| Net Cash Flow | −39 | −2 | 0 | 2 | 3 | −5 | 10 | −2 | 10 | −1 | −9 | 6 |
| Free Cash Flow | −10 | −26 | 0 | −2 | −19 | −6 | 9 | −2 | −1 | −8 | −29 | −76 |
| CFO/OP | 430 | −442 | −202 | 25 | 60 | 1,598 | 877 | 79 | 39 | 23 | 82 | 92 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 243 | 286 | 196 | 148 | 86 | 109 | 122 | 132 | 142 | 149 | 156 | 186 |
| Inventory Days | 124 | 110 | 84 | 39 | 36 | 70 | 35 | 28 | 10 | 18 | 53 | 33 |
| Days Payable | 124 | 154 | 184 | 108 | 33 | 89 | 525 | 239 | 200 | 118 | 189 | 230 |
| Cash Conversion Cycle | 243 | 241 | 96 | 79 | 89 | 89 | −367 | −79 | −48 | 50 | 20 | −11 |
| Working Capital Days | 197 | 234 | 115 | 93 | 37 | 22 | −223 | −40 | −4 | 30 | 56 | 49 |
| ROCE % | — | −10% | −9% | 5% | 6% | 1% | 3% | 6% | 10% | 13% | 16% | 13% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Kilitch Drugs insights
66 extracted metrics across FY11–FY27.
Documents
- Concall · Jun 2024Transcript
- Q4 FY23 concall · Jun 2023Transcript
- General announcements 23 Oct 2026
Frequently Asked Questions about Kilitch Drugs (India)
What does Kilitch Drugs (India) Ltd do?
Incorporated in 1978, Kilitch Drugs Ltd is engaged in the operation and management of Pharmaceutical Products
Where is Kilitch Drugs (India) Ltd (KILITCH) listed?
Kilitch Drugs (India) Ltd trades as KILITCH on the NSE and under code 524500 on the BSE.
Which sector does Kilitch Drugs (India) Ltd belong to?
Kilitch Drugs (India) Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Kilitch Drugs (India) Ltd?
Kilitch Drugs (India) Ltd trades at a PE ratio of 24.32 as of 4 Nov 2026, on earnings per share of ₹8.59, against a book value of ₹79.99 per share.
What is the 52-week high and low of Kilitch Drugs (India) Ltd?
Over the last 52 weeks Kilitch Drugs (India) Ltd has traded between ₹117.25 and ₹267.9 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Kilitch Drugs (India) Ltd?
Kilitch Drugs (India) Ltd reported a return on equity of 10.60%. Its debt-to-equity ratio is 0.32.
Company Information
Incorporated in 1978, Kilitch Drugs Ltd is engaged in the operation and management of Pharmaceutical Products
Website kilitch.com
CEO Mr. Mukund Prataprai Mehta B.Com., LL.B.
Employees 187
Listed 5 Mar 2002
Face Value ₹10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/KILITCH.md for Kilitch Drugs (India) Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.